Is Humira Approved for Rheumatoid Arthritis?
Yes, Humira (adalimumab) is FDA-approved for treating moderate to severe rheumatoid arthritis (RA) in adults. It reduces signs and symptoms, inhibits joint damage progression, and improves physical function when methotrexate is inadequate. Approval dates back to 2002 for RA, with ongoing use in combination therapy.[1][2]
How Does Humira Work for RA?
Humira is a tumor necrosis factor (TNF) blocker that targets inflammation-causing proteins in RA. Injected subcutaneously every other week, it interrupts cytokine signaling to ease joint pain, swelling, and stiffness.[1]
Who Can Use Humira for RA?
Adults with active RA who haven't responded well to one or more TNF blockers or methotrexate alone. Not for mild cases or monotherapy first-line. Pediatric approval exists for polyarticular juvenile idiopathic arthritis in kids 2+.[2]
Common Side Effects Patients Report with Humira for RA
Infections (upper respiratory, sinusitis), injection-site reactions, headache, and rash occur in >10% of users. Serious risks include tuberculosis reactivation, serious infections, lymphoma, and heart failure. Patients on RA therapy monitor for these via regular blood tests.[1][2]
How Does Humira Compare to Other RA Treatments?
| Treatment | Type | Dosing | Key Differences from Humira |
|-----------|------|--------|-----------------------------|
| Methotrexate | DMARD | Weekly oral/injectable | First-line, cheaper; Humira often added if insufficient. |
| Enbrel (etanercept) | TNF blocker | Weekly subcutaneous | Similar efficacy; interchangeable but different patents. |
| Xeljanz (tofacitinib) | JAK inhibitor | Daily oral | Oral alternative; higher infection/ clot risk. |
| Rituxan (rituximab) | B-cell depleter | IV infusion every 6 months | For TNF failures; targets different pathway. |
Humira shows 50-70% ACR response rates in trials, comparable to other biologics.[2]
When Does Humira's RA Patent Expire?
Core U.S. composition-of-matter patent expired in 2016, but method-of-use and formulation patents extend protection to 2023-2034 amid biosimilar challenges. AbbVie has defended 100+ patents; Amjevita (first biosimilar) launched 2023 via patent settlement.[3]
Cost and Access for RA Patients
List price ~$7,000/month, but copay cards and Medicare caps reduce out-of-pocket to $0-5 for many. Biosimilars like Hadlima cut costs 80-85%.[3]
Recent Challenges and Biosimilar Entry for RA
AbbVie faces ongoing litigation; nine biosimilars approved for RA, with Cyltezo interchangeable since 2023. Market share dropped from 98% to ~85% post-exclusivity.[3]
[1]: FDA Label - Humira (adalimumab) prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s441lbl.pdf
[2]: American College of Rheumatology RA Guidelines, https://rheumatology.org/rheumatoid-arthritis-guideline
[3]: DrugPatentWatch.com - Humira patents and exclusivity, https://www.drugpatentwatch.com/p/tradename/HUMIRA